ArticleJournal of pharmaceutical policy and practice2026
Antibiotic and antiviral prescribing patterns among hospitalised patients with COVID-19 pneumonia in Mongolia: a real-world descriptive retrospective study.
Article in Journal of pharmaceutical policy and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: During the COVID-19 pandemic, Mongolia, like many low- and middle-income countries, faced major healthcare delivery challenges due to limited system readiness, resource constraints, geopolitical vulnerabilities, and prolonged border closures. These factors caused shortages of laboratory reagents and globally recommended therapeutics, including remdesivir and tocilizumab, prompting clinicians to use alternative antivirals and empirical broad-spectrum antibiotics. Objective: To evaluate and compare real-world prescribing patterns of antibiotics and antivirals among hospitalised patients with COVID-19 pneumonia at Mongolia's two largest tertiary referral facilities: Mongolia-Japan Hospital (MJH) and the National Center for Communicable Diseases (NCCD). Methods: This retrospective cross-sectional study analysed anonymised medical charts and electronic health records of 1012 adults with PCR-confirmed COVID-19 pneumonia hospitalised between 18 April and 31 December 2021. Demographics, comorbidities, laboratory markers, and pharmacological treatments were systematically extracted and compared between the two institutions. Results: Antibiotics were prescribed to 87.6% (887/1012) of patients. Cephalosporins were the most frequently prescribed class (89.3%, 904/1012), followed by macrolides (36.5%, 369/1012) and fluoroquinolones (33.5%, 339/1012). Multi-drug empiricism was common, with beta-lactam, macrolide, and quinolone combinations accounting for 70.8% (68/96) of triple-antibiotic regimens. Antivirals were administered to over 90% of patients, predominantly umifenovir (52.2%) and favipiravir, supported by domestic stockpiles and Eurasian trade networks. Remdesivir was rarely used, while tocilizumab was administered to only 2 patients (0.2%). Hypertension and diabetes were significantly more frequent in the MJH cohort, reflecting differences in catchment populations and screening practices. Conclusion: The high rate of empirical broad-spectrum antibiotic use and reliance on alternative antivirals reflect pragmatic clinical adaptations to diagnostic reagent shortages and therapeutic supply inequities. These findings highlight the need for national antimicrobial stewardship programmes, strengthened microbiological diagnostic capacity, and digitised clinical registries to improve healthcare system resilience in resource-constrained settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.